2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 605

Decreased Frequencies of Circulating Follicular Helper T Cell Counterparts and Plasmablasts in Ankylosing Spondylitis Patients Naïve for TNF Blockers
Abstract Number: 637

Decreased Inflammatory Dendritic Cells in Lupus-Prone Estrogen Receptor Alpha Knockout (ERαKO) Mice Correlate with Increased Survival
Abstract Number: 2677

Decreased Levels of SRSF1 (Serin/Arginine-Rich Splicing Factor1) Induced Lower Levels of RasGRP1 in T Cells from Patients with Systemic Lupus Erythematosus
Abstract Number: 700

Decreased Lung Diffusion Capacity in Asymptomatic Patients with Systemic Lupus Erythematosus Does Not Predict Future Lung Disease
Abstract Number: 650

Decreased Severity of Pristane Induced Lupus in miR155 Deficient Mice
Abstract Number: 2094

Deep Sequencing Reveals Differential RNA Expression during Malignant Transformation in Major Salivary Glands in a Mouse Model of Sjogren’s Syndrome
Abstract Number: 1949

Defective PTEN Regulation and Function Contributes to B Cell Hyper-Responsiveness in Systemic Lupus Erythematosus
Abstract Number: 2087

Defective Regulation of L1 Endogenous Retroelements in Primary Sjogren’s Syndrome and Systemic Lupus Erythematosus: Role of Methylating Enzymes
Abstract Number: 2724

Deficiency of Ro52/TRIM21 in Different Subsets of Peripheral Blood Mononuclear Cells from Patients with Inflammatory Myopathies
Abstract Number: 1612

Deficient Repair of DNA Double-Strand Breaks and Increased Apoptosis in Patients with Lupus Nephritis
Abstract Number: 556

Defining Flare in Spondyloarthritis : Thresholds of Disease Activity Variations
Abstract Number: 2984

Degenerative Changes of the Spine on MRI in Patients with Inflammatory Back Pain from the DESIR Cohort
Abstract Number: 1157

Delay in Diagnosis from Onset of Symptoms By More Than One Year in 31% of Patients with Different Rheumatic Diseases in Australia
Abstract Number: 2794

Deletion of the Inhibitory Receptor Motif, ITIM, on DC-STAMP Alters Osteoclast Differentiation and Function
Abstract Number: 333

Deletion of the Prolactin Receptor Aggravates the Course of Antigen-Induced Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].